MA33702B1 - Nouveaux maytansinoïdes et utilisation desdits maytansinoïdes pour préparer des conjugués avec un anticorps - Google Patents

Nouveaux maytansinoïdes et utilisation desdits maytansinoïdes pour préparer des conjugués avec un anticorps

Info

Publication number
MA33702B1
MA33702B1 MA34818A MA34818A MA33702B1 MA 33702 B1 MA33702 B1 MA 33702B1 MA 34818 A MA34818 A MA 34818A MA 34818 A MA34818 A MA 34818A MA 33702 B1 MA33702 B1 MA 33702B1
Authority
MA
Morocco
Prior art keywords
represent
conjugates
mitonzinoid
antibodies
preparation
Prior art date
Application number
MA34818A
Other languages
Arabic (ar)
English (en)
Inventor
Alain Commercon
Claudia Fromond
Vincent Mikol
Fabienne Parker
Ingrid Sassoon
Hervé Bouchard
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41698152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33702(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33702B1 publication Critical patent/MA33702B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'INVENTION PORTE SUR UN COMPOSÉ DE FORMULE (I) : DANS LAQUELLE : ALK REPRÉSENTE UN GROUPE ALKYLÈNE EN C1-C6 ; X1 ET X2 REPRÉSENTENT CHACUN INDÉPENDAMMENT L'UN DES GROUPES SUIVANTS : -CH=CH-, -CO-, -CONR-, -NRCO-, -COO-, -OCO-, -OCONR-, -NRCOO-, -NRCONR'-, -NR-, -S(O)N (N = 0, 1 OU 2) OU -O- ; R ET R' REPRÉSENTENT CHACUN INDÉPENDAMMENT H OU UN GROUPE ALKYLE EN C1-C6 ; I REPRÉSENTE UN ENTIER DE 1 À 40, DE PRÉFÉRENCE DE 1 À 20 ET DE PRÉFÉRENCE ENCORE DE 1 À 10 ; J REPRÉSENTE UN ENTIER CORRESPONDANT À 1 LORSQUE X2 REPRÉSENTE -CH=CH- ET 2 LORSQUE X2 NE REPRÉSENTE PAS -CH=CH- ; ZB REPRÉSENTE UNE SIMPLE LIAISON, -O- OU -NH- ET RB REPRÉSENTENT H OU UN GROUPE ALKYLE EN C1-C6, CYCLOALKYLE EN C3-C7, ARYLE, HÉTÉROARYLE OU HÉTÉROCYCLOALKYLE EN C3-C7 ; OU ZB REPRÉSENTE UNE SIMPLE LIAISON ET RB REPRÉSENTE HAL. L'INVENTION PORTE ÉGALEMENT SUR L'UTILISATION DESDITS MAYTANSINOÏDES POUR PRÉPARER DES CONJUGUÉS AVEC UN ANTICORPS AYANT UNE AFFINITÉ POUR DES CELLULES TUMORALES.
MA34818A 2009-10-02 2012-04-27 Nouveaux maytansinoïdes et utilisation desdits maytansinoïdes pour préparer des conjugués avec un anticorps MA33702B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305939 2009-10-02
PCT/IB2010/054417 WO2011039721A1 (fr) 2009-10-02 2010-09-30 Nouveaux maytansinoïdes et utilisation desdits maytansinoïdes pour préparer des conjugués avec un anticorps

Publications (1)

Publication Number Publication Date
MA33702B1 true MA33702B1 (fr) 2012-10-01

Family

ID=41698152

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34818A MA33702B1 (fr) 2009-10-02 2012-04-27 Nouveaux maytansinoïdes et utilisation desdits maytansinoïdes pour préparer des conjugués avec un anticorps

Country Status (25)

Country Link
US (1) US20120276124A1 (fr)
EP (1) EP2483279A1 (fr)
JP (1) JP2013506653A (fr)
KR (1) KR20120091166A (fr)
CN (1) CN102741260A (fr)
AR (1) AR078471A1 (fr)
AU (1) AU2010302247A1 (fr)
BR (1) BR112012007305A2 (fr)
CA (1) CA2774916A1 (fr)
CL (1) CL2012000820A1 (fr)
CR (1) CR20120147A (fr)
EA (1) EA201270473A1 (fr)
EC (1) ECSP12011756A (fr)
IL (1) IL218740A0 (fr)
MA (1) MA33702B1 (fr)
MX (1) MX2012003998A (fr)
NI (1) NI201200051A (fr)
NZ (1) NZ599045A (fr)
PE (1) PE20121534A1 (fr)
PH (1) PH12012500649A1 (fr)
TN (1) TN2012000115A1 (fr)
TW (1) TW201117814A (fr)
UY (1) UY32913A (fr)
WO (1) WO2011039721A1 (fr)
ZA (1) ZA201202328B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
UY32914A (es) * 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
WO2012135517A2 (fr) 2011-03-29 2012-10-04 Immunogen, Inc. Préparation de conjugués de maytansinoïde anticorps par procédé en une étape
EA033468B1 (ru) 2011-03-29 2019-10-31 Immunogen Inc Способы получения конъюгата "антитело-майтансиноид"
EP2904089A4 (fr) 2012-10-04 2016-05-25 Immunogen Inc Utilisation d'une membrane de pvdf pour purifier des conjugués d'agent de liaison cellulaire-agent cytotoxique
ES2623209T3 (es) * 2012-10-24 2017-07-10 Polytherics Limited Conjugados fármaco-proteína
NO2789793T3 (fr) 2012-10-24 2018-01-27
CN104688740A (zh) * 2012-12-21 2015-06-10 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
EP3964237B1 (fr) 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Molécules biologiquement actives, leurs conjugués, et utilisations thérapeutiques
US20160143914A1 (en) * 2013-06-13 2016-05-26 Emory University Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof
AU2014311361B2 (en) 2013-08-26 2018-11-29 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
CN103483357B (zh) * 2013-10-12 2015-11-18 齐鲁制药有限公司 一种抗体-美登素偶联物的中间体新晶型及其制备方法
CN115504924A (zh) 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
CN105793268B (zh) * 2013-12-02 2019-03-15 香港浸会大学 具有两个稠合大环的抗癌性美登木素类化合物
GB201416960D0 (en) * 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
CA2966932A1 (fr) 2014-11-19 2016-05-26 Immunogen, Inc. Procede de preparation de conjugues agent de liaison cellulaire-agent cytotoxique
CA2978340C (fr) 2015-03-27 2024-05-28 Regeneron Pharmaceuticals, Inc. Derives de maytansinoide, conjugues de ceux-ci, et procedes d'utilisation
CN106267225B (zh) 2015-05-29 2020-03-06 上海新理念生物医药科技有限公司 三马来酰亚胺型连接子及其应用
EP3308801A4 (fr) 2015-06-09 2019-02-27 XDCExplorer (Shanghai) Co., Ltd. Conjugué anticorps-médicament, intermédiaire, procédé de préparation, compositions pharmaceutique et leurs utilisations
JP6638970B2 (ja) * 2015-06-30 2020-02-05 株式会社 東北テクノアーチ ヘテロ型単分散ポリエチレングリコール、ヘテロ型単分散ポリエチレングリコール製造用中間体の製造方法
WO2017083306A1 (fr) 2015-11-09 2017-05-18 R.P. Scherer Technologies, Llc Conjugués anticorps anti-her22-maytansine et méthodes d'utilisation de ceux-ci
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
TW201731532A (zh) 2016-02-05 2017-09-16 伊繆諾金公司 用於製備細胞結合劑-細胞毒性劑結合物之有效方法
US10195283B2 (en) * 2016-03-18 2019-02-05 R.P. Scherer Technologies, Llc Hydrazinyl-substituted heteroaryl compounds and methods for producing a conjugate
CN107652219B (zh) 2017-08-14 2021-06-08 上海新理念生物医药科技有限公司 四马来酰亚胺型连接子及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
CA2026147C (fr) 1989-10-25 2006-02-07 Ravi J. Chari Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1258255A1 (fr) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugués d'un anticorps contre CD44 et d'un maytansinoide
US6716821B2 (en) * 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
WO2004100885A2 (fr) * 2003-05-09 2004-11-25 The Trustees Of The University Of Pennsylvania Compositions et methodes de traitement anticancereux
EP1651162B1 (fr) 2003-05-20 2015-10-21 ImmunoGen, Inc. Agents cytotoxiques ameliores contenant de nouveaux maytansinoides
EA014640B1 (ru) 2003-07-21 2010-12-30 Иммьюноджен, Инк. Антитело или его эпитоп-связывающий фрагмент, которые связываются с гликотопом са6, и способы их применения
EP1669358A1 (fr) 2004-12-07 2006-06-14 Aventis Pharma S.A. Agents cytotoxiques comprenant des nouveau taxanes
NZ555308A (en) 2004-12-22 2010-10-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US7811572B2 (en) * 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
ATE535529T1 (de) 2005-08-09 2011-12-15 Millennium Pharm Inc Verfahren zur acylierung von maytansinol mit chiralen aminosäuren
EP1832577A1 (fr) 2006-03-07 2007-09-12 Sanofi-Aventis Promédicament amélioré d'analogues de CC-1065
EP1864682A1 (fr) 2006-06-09 2007-12-12 Sanofi-Aventis Dérivés de la Leptomycine
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
EP2185188B1 (fr) 2007-08-22 2014-08-06 Medarex, L.L.C. Attachement spécifique d'un site de médicaments ou autres agents à des anticorps synthétisés par génie génétique avec des extensions c-terminales
UA108598C2 (xx) * 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
UY32914A (es) * 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2

Also Published As

Publication number Publication date
CL2012000820A1 (es) 2012-08-31
JP2013506653A (ja) 2013-02-28
NZ599045A (en) 2013-09-27
KR20120091166A (ko) 2012-08-17
TW201117814A (en) 2011-06-01
AU2010302247A1 (en) 2012-04-26
CN102741260A (zh) 2012-10-17
EA201270473A1 (ru) 2013-02-28
TN2012000115A1 (en) 2013-09-19
US20120276124A1 (en) 2012-11-01
BR112012007305A2 (pt) 2016-12-06
CR20120147A (es) 2012-06-01
EP2483279A1 (fr) 2012-08-08
CA2774916A1 (fr) 2011-04-07
UY32913A (es) 2011-04-29
ZA201202328B (en) 2014-06-25
PH12012500649A1 (en) 2012-11-12
AR078471A1 (es) 2011-11-09
WO2011039721A1 (fr) 2011-04-07
ECSP12011756A (es) 2012-07-31
PE20121534A1 (es) 2012-12-03
NI201200051A (es) 2012-08-09
MX2012003998A (es) 2012-04-20
IL218740A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
PH12012500649A1 (en) New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
MX2008010481A (es) Compuestos que tienen afinado para el receptor f-ht6.
ZA200702700B (en) Diagnostic compounds
MX2009002492A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados.
WO2009023844A3 (fr) Composés substitués en position 3' ayant une affinité vis-à-vis du récepteur 5-ht<sb>6</sb>
MX2010003394A (es) Derivado de gamma-aminoacido biciclico.
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
WO2009151598A8 (fr) Diazacarbazoles et procédés d’utilisation
MA31690B1 (fr) Nouveaux fongicides
MA33761B1 (fr) Dispersion solide de rifaximine
MA31988B1 (fr) Derives d'aminopyrazole
AU2003291403A1 (en) 3-substituted-6-aryl pyridined as ligands of c5a receptors
MX2009003698A (es) Preparacion de azoxistrobina.
WO2009054497A1 (fr) Nouveau composé présentant une affinité pour l'amyloïde
WO2008083056A3 (fr) Ligands pour imagerie d'innervation cardiaque
WO2008120725A1 (fr) Nouveau dérivé de pyrrolinone et composition médicale le contenant
WO2008081631A1 (fr) Composé polymérisable et composition polymérisable
MX2009008324A (es) Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6.
WO2008147812A3 (fr) Composés 4' substitués ayant une affinité de récepteur 5-ht6
WO2005110416A3 (fr) 2-arylpyrimidines disubstituees en 4,5
MA32173B1 (fr) Derives de pyridin-2-yle utilises comme agents immunomodulateurs
MX2007009660A (es) Concentrado lubricante que contiene fosfato-triester.
MA31526B1 (fr) Nouveaux herbicides
TN2010000231A1 (fr) Derives de pyrazole servant d'inhibiteurs de 5-lo
IL189883A0 (en) Isoquinolines as igf-1r inhibitors